Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMFResearch in context
Sambad Sharma,
Shih-Ying Wu,
Hugo Jimenez,
Fei Xing,
Dongqin Zhu,
Yin Liu,
Kerui Wu,
Abhishek Tyagi,
Dan Zhao,
Hui-Wen Lo,
Linda Metheny-Barlow,
Peiqing Sun,
John D. Bourland,
Michael D. Chan,
Alexandra Thomas,
Alexandre Barbault,
Ralph B. D'Agostino,
Christopher T. Whitlow,
Volker Kirchner,
Carl Blackman,
Boris Pasche,
Kounosuke Watabe
Affiliations
Sambad Sharma
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Shih-Ying Wu
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Hugo Jimenez
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Fei Xing
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Dongqin Zhu
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Yin Liu
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Kerui Wu
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Abhishek Tyagi
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Dan Zhao
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Hui-Wen Lo
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Linda Metheny-Barlow
Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Peiqing Sun
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
John D. Bourland
Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Michael D. Chan
Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Alexandra Thomas
Department of Hematology and Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Alexandre Barbault
TheraBionic GmbH, Ettlingen, Germany
Ralph B. D'Agostino
Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Christopher T. Whitlow
Department of Radiology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Volker Kirchner
Genolier Cancer Center, Genolier, Switzerland
Carl Blackman
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Boris Pasche
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America
Kounosuke Watabe
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States of America; Corresponding author at: Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, Unites States of America
Background: Brain metastases are a major cause of death in patients with metastatic breast cancer. While surgical resection and radiation therapy are effective treatment modalities, the majority of patients will succumb from disease progression. We have developed a novel therapy for brain metastases that delivers athermal radiofrequency electromagnetic fields that are amplitude-modulated at breast cancer specific frequencies (BCF). Methods: 27.12 MHz amplitude-modulated BCF were administered to a patient with a breast cancer brain metastasis by placing a spoon-shaped antenna on the anterior part of the tongue for three one-hour treatments every day. In preclinical models, a BCF dose, equivalent to that delivered to the patient's brain, was administered to animals implanted with either brain metastasis patient derived xenografts (PDXs) or brain-tropic cell lines. We also examined the efficacy of combining radiation therapy with BCF treatment. Additionally, the mechanistic underpinnings associated with cancer inhibition was identified using an agnostic approach. Findings: Animal studies demonstrated a significant decrease in growth and metastases of brain-tropic cell lines. Moreover, BCF treatment of PDXs established from patients with brain metastases showed strong suppression of their growth ability. Importantly, BCF treatment led to significant and durable regression of brain metastasis of a patient with triple negative breast cancer. The tumour inhibitory effect was mediated by Ca2+ influx in cancer cells through CACNA1H T-type voltage-gated calcium channels, which, acting as the cellular antenna for BCF, activated CAMKII/p38 MAPK signalling and inhibited cancer stem cells through suppression of β-catenin/HMGA2 signalling. Furthermore, BCF treatment downregulated exosomal miR-1246 level, which in turn decreased angiogenesis in brain environment. Therefore, targeted growth inhibition of breast cancer metastases was achieved through CACNA1H. Interpretation: We demonstrate that BCF, as a single agent or in combination with radiation, is a novel treatment approach to the treatment of brain metastases. This paradigm shifting modality warrants further clinical trials for this unmet medical need. Keywords: Breast Cancer, Brain metastasis, Electromagnetic field, Radiofrequency, Calcium, Novel therapeutics, Cav3.2 T-type channel, Exosomes, Radiation, miRNA, Angiogenesis